Document:

Non-Exclusive Patent License Agmt

 EXHIBIT 10.10 

NON-EXCLUSIVE PATENT LICENSE AGREEMENT 

BETWEEN 

OSMETECH 

AND 

THE UNIVERSITY OF WASHINGTON 

UW REFERENCE: 7063-18921A 

UW TECHTRANSFER, INVENTION LICENSING 

NEGOTIATED BY CHRISTINE HAN, PH.D., M.P.H. 

 

 UW/Osmetech Non-Exclusive Patent License Agreement 

UW Reference 7063-18921A 

Original Two of Two 

Page 1 of 18 

 TABLE OF CONTENTS 

 

					
	 	  	 	  	Page
	1.0	  	 Definitions
	  	1
			
	2.0	  	 Term
	  	2
			
	3.0	  	 Grant of License
	  	2
			
	4.0	  	 Applications and Patents
	  	3
			
	5.0	  	 Commercialization
	  	4
			
	6.0	  	 Payments, Reimbursements, Reports, and Records
	  	5
			
	7.0	  	 Third Party Infringement of Licensed Patent
	  	6
			
	8.0	  	 Termination
	  	7
			
	9.0	  	 Release, Indemnification, and Insurance
	  	7
			
	10.0	  	 Warranties
	  	8
			
	11.0	  	 Damages
	  	9
			
	12.0	  	 Amendment and Waiver
	  	9
			
	13.0	  	 Assignment
	  	9
			
	14.0	  	 Applicable Law
	  	10
			
	15.0	  	 Confidentiality
	  	10
			
	16.0	  	 Consent and Approvals
	  	11
			
	17.0	  	 Construction
	  	11
			
	18.0	  	 Enforceability
	  	11
			
	19.0	  	 Entire Agreement; No Third-Party Beneficiaries
	  	11
			
	20.0	  	 Language and Currency
	  	11
			
	21.0	  	 Notices
	  	11
			
	22.0	  	 Publicity
	  	12
			
	23.0	  	 Relationship of Parties
	  	12
			
	24.0	  	 Security Interest
	  	12
			
	25.0	  	 Survival
	  	13
			
	26.0	  	 Collection Costs and Attorneys’ Fees
	  	13
			
	27.0	  	 Forum Selection
	  	13
			
	28.0	  	 Patent Marking
	  	13
			
		  	 Signatures
	  	13
			
		  	 Exhibit A
	  	14
			
		  	 Exhibit B
	  	16

 UW/Osmetech
Non-Exclusive Patent License Agreement 
 UW Reference 7063-18921A 

Original Two of Two 

 NON-EXCLUSIVE PATENT LICENSE AGREEMENT 

This Agreement (“Agreement”) is dated and effective as of the date of last signature (the “Effective
Date”), and is made by and between the University of Washington, a public institution of higher education and an agency of the state of Washington (the “University”), and Osmetech Molecular Diagnostics, an entity consisting solely of
Clinical Micro Sensors, Inc. and Osmetech, Inc., both Delaware Corporations (the “Company”), (individually a “Party” or collectively the “Parties”). 

Purpose 

The University owns the right to license to others certain rights to the Licensed Patents, as that term is defined and
used in this Agreement. The Company desires that the University grant it a license to use, develop, and commercialize the inventions claimed in the Licensed Patents. The University is willing to grant such a license on the terms set forth below.

 NOW, THEREFORE, the Parties agree that: 

1. Definitions. For purposes of interpreting this Agreement, the following terms shall have the meanings ascribed to them
below in this Article 1: 
  

	1.1	 “Affiliate” means (i) a Third Party that owns fifty percent (50%) or more of the voting capital stock, or like equity security,
of the Company, or (ii) a Third Party in which the Company owns fifty percent (50%) or more of the voting capital stock, or like equity security. 

 

	1.2	 “Confidential Information” means any information or materials (biological, chemical, or otherwise) of the Parties not generally known to
the public, including any information comprised by those materials and including without limitation, Licensed Technology. 

  

	1.3	 “Field of Use” means the fields of use described in section Al of attached Exhibit A. 

 

	1.4	 “Licensed Patent” means the patents and patent applications listed in section A2 of attached Exhibit A along with any further
related patent issued during the term of this Agreement by the United States Patent and Trademark Office or any like foreign body with respect to patent applications. The term “Licensed Patent” also includes any divisionals, continuations,
reissues, renewals, substitutions, re-examinations or extensions and foreign equivalents thereof or substitute therefore of a Licensed Patent. 

  

	1.5	 “Licensed Product” means any product, good or service in the Field of Use that is used, made by, made for, sold, transferred, offered for
sale, or otherwise disposed of by the Company during the term of this Agreement that, but for the granting of the rights set forth in this Agreement, would infringe (including under the doctrine of equivalents) one or more Valid Claims of a Licensed
Patent in the country where such product, good or service is sold or provided, or any product or good that is made using a process or 

 

					
		  	1	  	 UW/Osmetech Non-Exclusive Patent License Agreement

UW Reference 7063-18921A

Original Two of Two

Page 1 of 16

	 	 
machine that is covered by a Valid Claim of a Licensed Patent in the country where such product or good is sold or manufactured. 

 

	1.6	 “Licensed Technology” means collectively the inventions claimed in each Licensed Patent. 

 

	1.7	 “Net Sales Price” means the gross amount invoiced for sales, leases, services, and other dispositions of Licensed Products less
(i) all trade, quantity, and cash discounts actually allowed, including (ii) all credits and allowances actually granted due to rejections, returns, billing errors, and retroactive price reductions, (iii) duties, and (iv) excise,
sale and use taxes, and equivalent taxes. In the event the Company sells, leases, or disposes of a Licensed Product to an Affiliate, the “Net Sales Price” for that transaction for purposes of this Agreement shall be equal to the price the
Company charges non-Affiliate Third Parties for the Licensed Product or if the Company does not offer to sell the Licensed Product to the public, the price charged by the Company for a product of similar kind, quality, and quantity.

  

	1.8	 “Payment” means a payment to be made by the Company to the University specified in section 6.1 of this Agreement and described in
section A3 of attached Exhibit A. 

  

	1.9	 “Territory” means worldwide. 

  

	1.10	 “Third Party” means any individual or entity other than the University or the Company. 

 

	1.11	 “Valid Claim” means (a) a claim in an issued and unexpired patent included in the Licensed Patents that: (i) has not been held
unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction, and not subject to appeal, (ii) has not been admitted to be invalid or unenforceable through reissue or disclaimer or
otherwise, (iii) has not been lost through an interference, reexamination or reissue proceeding; or (b) a claim of a pending patent application included in the Licensed Patents. 

2. Term. The term of this Agreement shall commence on the Effective Date and, unless terminated earlier as provided below
in Article 8, this Agreement shall expire on the date on which no Valid Claim in a Licensed Patent is pending or subsisting in any country in the Territory. 

3. Grant of License. 
  

	3.1	 The Company’s Rights. 

3.1.1. Grant. Subject to the terms and conditions of this Agreement, the University hereby grants
to the Company, and the Company hereby accepts, a nonexclusive license to make, have made on its behalf, use, offer to sell or sell, offer to lease or lease, import, or otherwise offer to dispose or dispose of Licensed Products in the Territory. The
Parties acknowledge and agree that the license granted in this Agreement 
  

					
		  	2	  	 UW/Osmetech Non-Exclusive Patent License Agreement

UW Reference 7063-18921A

Original Two of Two

Page 2 of 16

 
shall be limited to the inventions in the Field of Use that are expressly claimed in each Licensed Patent. No provision of this Agreement shall be construed to grant the Company, by implication,
estoppel or otherwise, any rights other than the rights expressly granted it in this Agreement to the Licensed Technology, a Licensed Patent, or to any other University-owned technology, patent applications, or patents. 

3.1.2. Sublicensing. Notwithstanding any term of this Agreement to the contrary, the Company shall
not, and shall not have the right to, sublicense its rights under this Agreement. 
  

	3.2	 The United States Government’s Rights. The Parties acknowledge and agree that the federal government of the United States of America has
certain rights in and to any government-funded Licensed Technology as those rights are described in Chapter 18, Title 35 of the United States Code and accompanying regulations, including Part 401, Chapter 37 of the Code of Federal
Regulations, and that the Parties’ rights and obligations under this Agreement to any government-funded Licensed Technology, including the grant of license set forth above in subsection 3.1.1, are subject to the applicable terms of the
aforementioned United States laws. 

  

	3.3	 The University’s Rights. The University retains an irrevocable, nonexclusive license to make, have made, and use products, processes,
and other subject matter covered by the Licensed Patents or the Licensed Technology for research, medical, instructional, or any other academic purpose, including publications. 

4. Applications and Patents. 
  

	4.1	 Cost Reimbursement. The Company shall pay, or shall reimburse the University for paying, reasonable and necessary costs (including
attorneys’ and application fees) incurred prior to, on, or after the Effective Date to apply for, prosecute, enforce, and maintain each Licensed Patent in those countries where the Company intends to commercialize Licensed Product, as provided
for in section A3.6 of attached Exhibit A. For the avoidance of doubt, the Company shall pay, or shall reimburse the University for paying, costs related to Licensed Patents unless and until the Company notifies the University in writing
of its decision to opt-out of patent protection for a specific country in the Territory. In this event, the Company shall not be responsible for reimbursing those costs and lose rights in that country. 

 

	4.2	 Pre-Agreement Licensed Product Sales. The Company agrees to pay royalties in the amounts set forth in this Agreement for any Licensed
Products it has sold in the Territory prior to the Effective Date. 

  

	4.3	 Patent Application Filings during the Term of this Agreement. 

4.3.1. The University retains the sole and exclusive right to file or otherwise prosecute patent
applications with respect to the Licensed Technology. In no event shall 
  

					
		  	3	  	 UW/Osmetech Non-Exclusive Patent License Agreement

UW Reference 7063-18921A

Original Two of Two

Page 3 of 16

 
the Company file a patent application with respect to the Licensed Technology if a University employee is an inventor on the patent application. 

4.3.2. The University shall determine in which countries the University will file, or cause to be filed,
a patent application with respect to the Licensed Technology. The Company may request patent prosecution to be pursued in any given country. The Company will specify in writing which of these countries it wishes to receive license from and shall pay
pro-rata share of patent costs as specified in section A3.6 of attached Exhibit A. For the avoidance of doubt, Company shall pay, or shall reimburse the University for paying costs related to Licensed Patents in all countries until the
Company notifies the University in writing of its decision to opt-out of said cost reimbursement for any specific country. 

4.3.3. For each patent application with respect to the Licensed Technology filed in a particular country,
the University shall retain counsel of its choice to file and prosecute such patent application; the University shall take all commercially reasonable steps to cause a patent application to be filed and a patent to be issued in that country. The
Company promptly shall reimburse the University for the University’s out-of-pocket costs, including application and attorneys’ fees, to file, prosecute and maintain such patent application and issued patent during the term of this
Agreement as provided for in section A3.4 of attached Exhibit A. 
 4.3.4. No provision
of this Agreement limits, conditions, or otherwise affects the University’s right to prosecute a patent application with respect to the Licensed Technology in any country. 

 

	4.4	 Maintenance of Licensed Patents. The University shall take all commercially reasonable steps to cause each Licensed Patent to remain or be
valid and subsisting. 

  

	4.5	 Ownership of the Licensed Patents. No provision of this Agreement grants the Company any rights, titles, or interests (except for the grant
of license in subsection 3.1.1 of this Agreement) in the Licensed Patents, notwithstanding the Company’s payment of all or any portion of the patent prosecution, maintenance, and related costs. 

5. Commercialization. 
  

	5.1	 Commercialization Efforts. The Company shall use its commercially reasonable efforts, consistent with sound and reasonable business practices
and judgment, to commercialize the Licensed Technology and to manufacture and offer to make and sell Licensed Products as soon as practicable and to maximize sales thereof. 

 

	5.2	 Covenants Regarding the Manufacture of Licensed Products. The Company hereby covenants and agrees that the manufacture, use, sale, or
transfer of Licensed Products shall comply with all applicable federal and state laws, including all federal export laws and regulations. The Company hereby further covenants and agrees that, to the extent required by 35 United States Code
Section 204, it shall substantially manufacture in the 

  

					
		  	4	  	 UW/Osmetech Non-Exclusive Patent License Agreement

UW Reference 7063-18921A

Original Two of Two

Page 4 of 16

	 	 
United States of America all products embodying or produced through the use of an invention that is subject to the rights of the federal government of the United States of America.

  

	5.3	 Commercialization Reports. Throughout the term of this Agreement, the Company shall deliver to the University written reports of the
Company’s efforts and plans to commercialize the Licensed Technology and to manufacture, offer to sell, or sell Licensed Products, including a projected timeline of development and sales. Prior to product introduction, these reports will be
delivered to the University every six (6) months from the first anniversary of the Effective Date, and then annually, within thirty (30) days of the anniversary of the Effective Date, after first product sale. 

 

	5.4	 Use of the University’s Name and Trademarks or the Names of University Faculty, Staff, or Students. No provision of this Agreement
grants the Company any right or license to use the name or trademarks of the University or the names, or identities of any member of the faculty, staff, or student body of the University. The Company shall not use any such trademarks, names, or
identities without the University’s and, as the case may be, such member’s prior written approval. 

6. Payments, Reimbursements, Reports, and Records. 

 

	6.1	 Payments. The Company shall deliver to the University the payment or payments specified in section A3 of attached Exhibit A. The
Company shall make such payments by check, wire transfer, or any other mutually agreed-upon and generally accepted method of payment. All checks to the University shall be made payable to “University of Washington” and shall be mailed to
the address specified in Article 21 of this Agreement and shall include the University agreement number l8921A. Upon request, the University shall deliver to the Company written wire transfer instructions. 

 

	6.2	 Late Payments. Company agrees to pay a late fee for all amounts owed to the University that are overdue by thirty (30) days or more. The
late fee shall be computed as the United States prime rate plus Two Percent (2%), compounded monthly, as set forth by The Wall Street Journal (Western edition) on the date on which such payment is due, of the outstanding, unpaid balance. The
payment of such a late fee shall not foreclose or limit University from exercising any other rights it may have as a consequence of the lateness of any payment. 

 

	6.3	 Sales Reports. Within thirty (30) days after the last day of a calendar quarter during the term of this Agreement, the Company shall
deliver to the University a written sales report (a copy of the form of which is attached as Exhibit B) recounting the number and Net Sales Price amount (expressed in U.S. dollars) of all sales, leases, or other dispositions of Licensed
Products made by the Company during such calendar quarter. The Company shall deliver such written report to the University even if the Company is not required hereunder to pay to the University a payment for sales, leases, or other dispositions of
Licensed Products during the calendar quarter. 

  

					
		  	5	  	 UW/Osmetech Non-Exclusive Patent License Agreement

UW Reference 7063-18921A

Original Two of Two

Page 5 of 16

	6.4	 Records Retention and Audit Rights. 

6.4.1. Throughout the term of this Agreement and for five (5) years thereafter, the Company, at its
expense, shall keep and maintain complete and accurate records of all sales, leases, and other dispositions of Licensed Products during the term of this Agreement and all other records related to this Agreement. 

6.4.2. The University, at its expense except as set forth below in this subsection, shall have the right
to inspect and audit the Company’s records referred to in subsection 6.4.1 hereof at the Company’s address as set forth in Article 21 of this Agreement or such other locations as the Parties shall mutually agree during the
Company’s normal business hours. The University shall have the right to determine the Company’s compliance with the terms of this Agreement. The Company shall reimburse the University for all its out-of-pocket expenses to inspect and audit
such records if the University, in accordance with the results of such inspection and audit, determines that the Company has underpaid amounts owed to the University by at least *** percent (***%), in a reporting period. In connection with, and
prior to the commencement of, an audit, if the Company so requests in writing to the University, the Company, the University and the auditor shall enter into an agreement prohibiting the auditor and the University from disclosing the Company’s
nonpublic, proprietary information to any Third Party without the Company’s prior written consent; provided, however, that consistent with generally accepted auditing standards and the auditor’s professional judgment, the auditor may
disclose such information to the University and its agents, counsel, or consultants. The Company acknowledges that such an agreement is adequate to protect its legitimate interests, and the Parties agree that there shall be no additional
nondisclosure agreement demanded as a condition to the commencement of an audit and the University’s exercising its rights under this subsection. 
  

	6.5	 Currency and Checks. All computations and payments made under this Agreement shall be in United States dollars. The exchange rate for the
currency into dollars as reported in the Wall Street Journal as the New York foreign exchange mid-range rate on the last business day of the month in which the transaction was entered into shall be used for determining the dollar value of
transactions conducted in non-United States dollar currencies. 

 7. Third Party Infringement of Licensed
Patent. 
  

	7.1	 Notice of Third Party’s Infringement. In the event the Company learns of substantial, credible evidence that a Third Party is making,
using, or selling a product in a Field of Use in the Territory that infringes a Licensed Patent, the Company promptly thereafter shall deliver written notice of the possible infringement to the University, describing the information suggesting
infringement of the Licensed Patent. 

  

	***	 Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.

  

					
		  	6	  	 UW/Osmetech Non-Exclusive Patent License Agreement

UW Reference 7063-18921A

Original Two of Two

Page 6 of 16

	7.2	 Legal Action to Enforce a Licensed Patent. The University shall have no obligation under this Agreement to commence or maintain a suit
against any alleged infringer of Licensed Patents. The University reserves the right to grant a license to the infringer to settle a University-initiated action. No provision of this Agreement shall limit, condition, or otherwise affect the
University’s statutory and common-law rights to commence an action to enforce a Licensed Patent. 

 8.
Termination. 
  

	8.1	 By the University. 

8.1.1. If the Company breaches or fails to perform one or more of its duties under this Agreement, the
University may deliver to the Company a written notice of default. The University may terminate this Agreement by delivering to the Company a written notice of termination if the default has not cured in full within sixty (60) days of the
delivery to the Company of the notice of default. 
 8.1.2. The University may terminate this
Agreement by delivering to the Company a written notice of termination at least ten (10) days prior to the date of termination if the Company (i) becomes insolvent; (ii) voluntarily files or has filed against it a petition under
applicable bankruptcy or insolvency laws that the Company fails to have released within thirty (30) days after filing; (iii) proposes any dissolution, composition, or financial reorganization with creditors or if a receiver, trustee,
custodian, or similar agent is appointed; or (iv) makes a general assignment for the benefit of creditors. 
  

	8.2	 By the Company. The Company may terminate this Agreement at any time by delivering to the University a written notice of termination at least
sixty (60) days prior to the effective date of termination. 

  

	8.3	 Post-termination Period. The Company shall not use, or permit others to use, the Licensed Technology or manufacture or have manufactured
Licensed Products after the termination of this Agreement under section 8.1 or 8.2. After the termination of this Agreement under section 8.1 or 8.2, the Company shall not offer to sell and sell, offer to lease and lease, and otherwise
offer to dispose of or dispose of Licensed Products in the Territory that were manufactured prior to the of this Agreement. 

9. Release, Indemnification, and Insurance. 
  

	9.1	 The Company’s Release. For itself and its employees, the Company hereby releases the University and its regents, employees, and agents
forever from any and all suits, actions, claims, liabilities, demands, damages, losses, or expenses (including reasonable attorneys’ and investigative expenses) relating to or arising out of (i) the manufacture, use, lease, sale, or other
disposition of a Licensed Product; (ii) the assigning or licensing of the Company’s rights under this Agreement; or (iii) with the exception of the 

 

					
		  	7	  	 UW/Osmetech Non-Exclusive Patent License Agreement

UW Reference 7063-18921A

Original Two of Two

Page 7 of 16

	 	 
warranties set forth in section 10.1 of this Agreement, the University’s performance of its obligations hereunder. 

 

	9.2	 Indemnification. Throughout the term of this Agreement and thereafter, the Company shall indemnify, defend, and hold the University and its
regents, employees, and agents harmless from all suits, actions, claims, liabilities, demands, damages, losses, or expenses (including reasonable attorneys’ and investigative expenses), relating to or arising out of any default in the
performance of any material term or provision herein. In addition, throughout the term of this Agreement and thereafter, the Company shall indemnify, defend, and hold the University and its regents, employees, and agents harmless from all suits,
actions, claims, liabilities, demands, damages, losses, or expenses (including reasonable attorneys’ and investigative expenses), relating to or arising out of the manufacture, use, lease, sale, or other disposition of a Licensed Product,
including, without limitation, breach of contract and warranty and products-liability claims relating to a Licensed Product. 

  

	9.3	 The Company’s Insurance. Throughout the term of this Agreement, or during such period as the Parties shall agree in writing, the Company
shall maintain in full force and effect comprehensive general liability (CGL) insurance, consistent with sound business practices. Such insurance policy shall include coverage for claims that may be asserted by the University against the Company
under section 9.2 of this Agreement and for claims by a Third Party against the Company or the University arising out of the purchase or use of a Licensed Product. Such insurance policy shall name the University as an additional insured. Such
insurance policy shall require the insurer to deliver written notice to the University at the address set forth in Article 21 of this Agreement, at least forty-five (45) days prior to the termination of the policy. The Company shall
deliver to the University a copy of the certificate of insurance for such policy. 

 10. Warranties. 

  

	10.1	 Authority. Each Party represents and warrants to the other Party that it has full corporate power and authority to execute, deliver, and
perform this Agreement, and that no other corporate proceedings by such Party are necessary to authorize the Party’s execution or delivery of this Agreement. 

 

	10.2	 Disclaimers. 

10.2.1. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN SECTION 10.1 OF THIS AGREEMENT, THE
UNIVERSITY DISCLAIMS AND EXCLUDES ALL WARRANTIES, EXPRESS AND IMPLIED, CONCERNING THE LICENSED TECHNOLOGY, EACH LICENSED PATENT, EACH PATENT APPLICATION, AND EACH LICENSED PRODUCT, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF NON-INFRINGEMENT,
NONINTERFERENCE AND THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. 
  

					
		  	8	  	 UW/Osmetech Non-Exclusive Patent License Agreement

UW Reference 7063-18921A

Original Two of Two

Page 8 of 16

 10.2.2. The University expressly disclaims any warranties
concerning and makes no representations: 
 10.2.2.1. that the Licensed Patents will be approved or will issue;

 10.2.2.2. concerning the validity or scope of any Licensed Patent; or 

10.2.2.3. that the manufacture, use, sale, lease or other disposition of a Licensed Product will not infringe a Third
Party’s patent or violate its intellectual property rights. 
 10.2.3. The Company
specifically acknowledges the existence of possibly interfering patent rights of Third Parties, including, without limitation, certain patent rights of University of North Carolina (Patent Application Number WO2005030039A2) and Academica Sinica
(Patent Application Number WO2006069339A2). 
  

	11.	 Damages. 

  

	11.1	 Remedy Limitation. EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, IN NO EVENT SHALL THE UNIVERSITY BE LIABLE FOR (A) PERSONAL
INJURY OR PROPERTY DAMAGES ARISING IN CONNECTION WITH THE ACTIVITIES CONTEMPLATED IN THIS AGREEMENT OR (B) LOST PROFITS, LOST BUSINESS OPPORTUNITY, INVENTORY LOSS, WORK STOPPAGE, LOST DATA OR ANY OTHER RELIANCE OR EXPECTANCY, DIRECT OR
INDIRECT, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES, OF ANY KIND. 

  

	11.2	 Damage Cap. IN NO EVENT SHALL THE UNIVERSITY’S TOTAL LIABILITY FOR THE BREACH OR NONPERFORMANCE OF THIS AGREEMENT EXCEED THE AMOUNT
OF PAYMENTS PAID TO THE UNIVERSITY UNDER SECTION 6.1 OF THIS AGREEMENT. THIS LIMITATION SHALL APPLY TO CONTRACT, TORT, AND ANY OTHER CLAIM OF WHATEVER NATURE. 

12. Amendment and Waiver. This Agreement may be amended from time to time only by a written instrument signed by the
Parties. No term or provision of this Agreement shall be waived and no breach excused unless such waiver or consent shall be in writing and signed by the Party claimed to have waived or consented. No waiver of a breach shall be deemed to be a waiver
of a different or subsequent breach. 
 13. Assignment. The Company, without the prior approval of the University,
may assign all, but no less than all, its rights and delegate all, but no less than all, its duties under this Agreement to another if (i) the Company or its successors delivers to the University written notice of the actual assignment at least
ninety (90) days prior to the effective date of the event described below in part (ii) of this paragraph, and (ii) the assignment is made as a part of and in connection with (A) the sale by the Company of all or substantially all
of its assets to a single purchaser, (B) the sale, transfer, or exchange by the shareholders, partners, or equity owners of the Company of 

 

					
		  	9	  	 UW/Osmetech Non-Exclusive Patent License Agreement

UW Reference 7063-18921A

Original Two of Two

Page 9 of 16

 
a majority interest in the Company to a single purchaser, or (C) the merger of the Company into another corporation or other business entity. Any assignment made in violation of this
subsection shall be void and shall, without further act, cause the immediate termination of this Agreement. 
 This
Agreement shall inure to the benefit of the Company and the University and trustees. 
 14. Applicable Law. The
internal laws of the state of Washington shall govern the validity, construction, and enforceability of this Agreement, without giving effect to the conflict of laws principles thereof. 

15. Confidentiality. 
  

	15.1	 Form of transfer. Confidential Information may be conveyed in written, graphic, oral, physical, or electronic form. Confidential Information
shall include, without limitation, Licensed Technology as well as Company’s business plan or reports. Company and University must clearly mark its Confidential Information “confidential.” If a disclosing Party communicates
Confidential Information orally, the disclosing Party shall reduce such oral communications to writing of disclosure to the receiving Party and clearly mark it “confidential” and provide a copy to the receiving Party within thirty
(30) days at the address in Article 21. 

  

	15.2	 Exceptions. Confidential Information does not include: any information that: is required by law to be disclosed; is or becomes part of the
public domain through no fault of recipient; is known to recipient prior to the disclosure by the disclosing Party, as evidenced by documentation; is publicly released as authorized under this Agreement by the University, its employees or agents; is
subsequently obtained by a Party from a Third Party who is authorized to have such information; or is independently developed by a Party without reliance on any portion of the Confidential Information received from the disclosing Party and without
any breach of this Agreement as evidenced by documentation. 

  

	15.3	 No Unauthorized Disclosure of Confidential Information. Beginning on the Effective Date and continuing throughout the term of this Agreement
and thereafter for a period of five (5) years (“Confidentiality Period”), neither Party shall disclose or otherwise make known or available to any Third Party or Affiliate any Confidential Information, without the express prior
written consent of the other. In no event shall either Party incorporate or otherwise use Confidential Information in connection with any patent application filed by or on behalf of the other. Both Parties shall utilize reasonable procedures to
safeguard the Confidential Information. 

  

	15.4	 Access to University Information. The University is an agency of the State of Washington and is subject to the Washington Public Records Act,
RCW 42.56 et seq., (“Act”), and no obligation assumed by the University under this Agreement shall be deemed to be inconsistent with the University’s obligations as defined under the Act and as interpreted by the University in its
sole discretion. In the event the University receives 

  

					
		  	10	  	 UW/Osmetech Non-Exclusive Patent License Agreement

UW Reference 7063-18921A

Original Two of Two

Page 10 of 16

	 	 
a request for public records under the Act for documents containing Confidential Information, and if the University concludes that the documents are not otherwise exempt from public disclosure,
the University will provide the Company notice of the request before releasing such documents. Such notice shall be provided in a timely manner to afford the Company sufficient time to review such documents and/or seek a protective order, at the
Company’s expense utilizing the procedures described in RCW 42.56.540. The University shall have no obligation to protect the Confidential Information from disclosure in response to a request for public records. 

16. Consent and Approvals. Except as otherwise expressly provided, all consents or approvals required under the terms of
this Agreement shall be in writing and shall not be unreasonably withheld or delayed. 
 17. Construction. The
headings preceding and labeling the sections of this Agreement are for the purpose of identification only and shall not in any event be employed or used for the purpose of construction or interpretation of any portion of this Agreement. As used
herein and where necessary, the singular shall include the plural and vice versa, and masculine, feminine, and neuter expressions shall be interchangeable. 

18. Enforceability. If a court of competent jurisdiction adjudges a provision of this Agreement unenforceable, invalid, or
void, such determination shall not impair the enforceability of any of the remaining provisions hereof and such provisions shall remain in full force and effect. 

19. Entire Agreement; No Third-Party Beneficiaries. This Agreement (including all attachments, exhibits, and amendments
hereto) is intended by the Parties as the final and binding expression of their contract and agreement and as the complete and exclusive statement of the terms thereof. This Agreement cancels, supersedes, and revokes all prior negotiations,
representations and agreements among the Parties, whether oral or written, relating to the subject matter of this Agreement. 

Company has evaluated the Licensed Technology under a Confidentiality Agreement (“Confidentiality Agreement”) with University
(UWIL # 18127A) with an effective date of August 2, 2006. Confidentiality Agreement is hereby supplanted entirely by this Agreement. 

No provision of this Agreement, express or implied, is intended to confer upon any person other than the Parties to this Agreement any
rights, remedies, obligations, or liabilities hereunder. 
 20. Language and Currency. Unless otherwise expressly
provided in this Agreement, all notices, reports, and other documents and instruments that a Party hereto elects or is required by the terms of this Agreement to deliver to the other Party hereto shall be in English, and all notices, reports, and
other documents and instruments detailing revenues and earned under this Agreement or expenses chargeable to a Party hereto shall be United States dollar denominated. 

21. Notices. All notices, requests, and other communications that a Party is required or elects to deliver shall be in
writing and shall be delivered personally, or by facsimile or 
  

					
		  	11	  	 UW/Osmetech Non-Exclusive Patent License Agreement

UW Reference 7063-18921A

Original Two of Two

Page 11 of 16

 
electronic mail (provided such delivery is confirmed), or by a recognized overnight courier service or by United States mail, first-class, certified or registered, postage prepaid, return receipt
requested, to the other Party at its address set forth below or to such other address as such Party may designate by notice given pursuant to this article: 
  

			
	 If to the University:
	  	 UW TechTransfer Invention Licensing

ATTN: Director

4311
11th Avenue NE, Suite 500

Seattle, WA 98105-4608

Facsimile No.: 206-685-4767

		
	For notices sent pursuant to Article 8, with a copy to:	  	 University of Washington

Office of the Attorney General

101 Gerberding Hall

Seattle, WA 98105

Facsimile No: 206-543-0779

		
	 If to the Company:
	  	 Osmetech

ATTN: Legal Department

757 S. Raymond Ave.

Pasadena, CA 91105

Facsimile: 626 463 2012

22. Publicity. Nothing contained in this Agreement shall be construed as conferring any right to use in advertising,
publicity or other promotional activities any name, trade name, trademark, or other designation of the University without the express written permission of the University, unless such listing is required under local laws or regulations, provided
that the Company may state the existence of this Agreement and the fact that both Parties entered into it. For any use other than the foregoing, the Company hereby expressly agrees not to use the name “University of Washington” or any
contraction, abbreviation, or simulation thereof without prior written approval from an authorized representative of the University. The University shall have the right to report in its customary publications and presentations that the University
and the Company have entered into a license agreement for the Licensed Technology and the University may use the Company logos in such publications and presentations provided that the University does not modify the Company’s logos and does not
through such use imply any endorsement by the Company of the University. 
 23. Relationship of Parties. In
entering into, and performing their duties under, this Agreement, the Parties are acting as independent contractors and independent employers. No provision of this Agreement shall create or be construed as creating a partnership, joint venture, or
agency relationship between the Parties. No Party shall have the authority to act for or bind the other Party in any respect. 

24. Security Interest. In no event shall the Company grant, or permit any person to assert or perfect, a security interest
in the Company’s rights under this Agreement. 
  

					
		  	12	  	 UW/Osmetech Non-Exclusive Patent License Agreement

UW Reference 7063-18921A

Original Two of Two

Page 12 of 16

 25. Survival. Immediately upon the termination or expiration of this
Agreement, all the Company’s rights under this Agreement shall terminate; provided, however, the Company’s obligations that have accrued prior to the effective date of termination or expiration of this Agreement (e.g., the
obligation to report and make payments on sales, leases, or dispositions of Licensed Products and to reimburse the University for costs) and the obligations specified in sections 6.1, 6.2, and A3.1 of the Agreement shall survive. The
obligations and rights set forth in sections 6.4 and 8.3 and articles 9, 10, and 11 of this Agreement shall survive the termination or expiration of this Agreement. 

26. Collection Costs and Attorneys’ Fees. If a Party shall fail to perform an obligation or otherwise breaches one or
more of the terms of this Agreement, the other Party may recover from the non-performing breaching Party all its costs (including actual attorneys’ and investigative fees) to enforce the terms of this Agreement. 

27. Forum Selection. A suit, claim, or other action to enforce the terms of this Agreement shall be brought exclusively in
the state courts of King County, Washington. The Company hereby submits to the jurisdiction of that court and waives any objections it may have to that court asserting jurisdiction over the Company or its assets and property. 

28. Patent Marking. Company shall mark any and all material forms of Licensed Product or packaging pertaining thereto made
and sold by Company in the Territory with patent marking confirming to 35 U.S.C. §287(a), as amended from time to time. Such marking shall further identify the pendency of any U.S. patent application and/or any issued U.S. or foreign patent
forming any part of the University rights. All Licensed Product shipped to or sold in other countries shall be marked in such a manner as to provide notice to potential infringers pursuant to the patent law and practice of the country of manufacture
or sale. 
 IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed by their respective authorized
representatives. 
  

									
	 University of Washington
	 		 	 Osmetech Molecular Diagnostics

					
	 By:
	 	 /s/ Fiona Wills
	 		 	 By:
	 	 /s/ Edward O. Kreusser

	 Name:
	 	 Fiona Wills
	 		 	 Name:
	 	 Edward O. Kreusser, Esq.

	 Title:
	 	 Interim Director
	 		 	 Title:
	 	 VP, IP and Legal Affairs

					
	 Date:
	 	 February 22, 2007
	 		 	 Date:
	 	 2/28/2007

 

					
		  	13	  	 UW/Osmetech Non-Exclusive Patent License Agreement

UW Reference 7063-18921A

Original Two of Two

Page 13 of 16

 Exhibit A 

Non-Exclusive Patent License Schedule 
  

	A1.	 Fields of Use (sections 1.2 and 3.1.1): 

Fields of Use: Human clinical diagnostics field, including Research Use Only (RUO), Investigational Use Only, (IUO),
Analyte Specific Reagents (ASR), and In Vitro Diagnostic (IVD) fields of use for anticoagulant dosing. IVD field of use expressly excludes market for tests performed in the home. Any reagents or kits sold under this Agreement are not for
remanufacture, re-kitting, or resale to any Third Party, in whole or part. 
  

	A2.	 Licensed Patents (section 1.4): 

  

									
	 Patent Application No.:
	  	 UW Reference #
	  	 Inventors
	  	 Assignee
	  	Application
Date
	 US 10/967,879
	  	 7063P.1US
	  	 Mark Rieder Allan Rettie
	  	 University of Washington
	  	10/18/2004
	 PCT/US2005/037058
	  	 7063P.IPCT
	  	 Mark Rieder Allan Rettie
	  	 University of Washington
	  	10/17/2005
	 US 11/141,288
	  	 7063P.1USCIP1
	  	 Mark Rieder Allan Rettie
	  	 University of Washington
	  	05/31/2005

  

	A3.	 Payments (section 6.1): 

  

	A3.1	 Up-front Payment. The Company shall pay to the University *** dollars ($***) as an up-front payment. This up-front payment shall be due as of
the Effective Date and payable in *** dollars ($***). The first installment shall be payable within thirty (30) days of the Effective Date. The next installment shall be payable within thirty (30) days of the first anniversary of the
Effective Date and the last installment shall be payable within thirty (30) days of the second anniversary of the Effective Date. This up-front payment shall be non-refundable and not creditable against future royalty obligations and shall
survive termination or expiration of this Agreement. 

  

	A3.2	 Running Royalty Payments. The Company shall pay to the University within thirty (30) days after the last day of each calendar quarter
during the term of this Agreement an amount equal to *** percent (***%) of the Net Sales Price of all sales, leases, or dispositions of Licensed Products made by the Company during such quarter as a running royalty payment. In the event that Company
is required to pay royalties to one or more Third Parties as necessary to avoid infringement thereof by the manufacture, use, or sale of any Licensed Products, or to avoid infringement-related litigation with respect to such patents, then the
running royalty rate specified shall be reduced by an amount equal to one-half of the royalties actually paid to the Third Party, provided that in no event shall the royalties otherwise due to the University be less than *** percent (***%) of the
royalties that 

  

	***	 Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.

  

					
		  	14	  	 UW/Osmetech Non-Exclusive Patent License Agreement

UW Reference 7063-18921A

Original Two of Two

Page 14 of 16

	 	
would be payable to the University were the University the sole licensor with respect to such Licensed Products. For the avoidance of doubt, under no circumstance shall the royalty to the
University be less than *** percent (***%) of Net Sales Price following such reduction. 

  

	A3.3	 Combination Products. If a Licensed Product is sold in combination with one or more other products or components that is not a Licensed
Product, Net Sales Price shall be calculated by multiplying Net Sales Price for such combination product by the fraction    ***    where A is the invoice price if the Licensed Product is sold separately, and B
is the aggregate invoice price of any other active component or components, or devices, in the combination if sold separately, or if either of the products are not sold separately, than the allocation shall be commercially reasonable and determined
by good faith negotiation between the University and the Company. Notwithstanding the foregoing, in no event shall the royalties due the University be less than *** percent (***%) of what would otherwise be due if the Licensed Product was sold as an
individual product. 

  

	A3.4	 Annual Minimum Royalty Payments. The Company shall pay to the University within thirty (30) days after each anniversary of the Effective
Date, annual minimum royalties, to be creditable against running royalties for the preceding year on a non-cumulative basis, as set forth in the following table: 

 

			
	 Due on Anniversary Date of Year #:
	  	$ Amount in USD
	 1
	  	***
	 2
	  	***
	 3
	  	***
	 4
	  	***
	 5 and each year thereafter
	  	***

  

	A3.6	 Patent Prosecution Reimbursements: The Company shall pay to the University within thirty (30) days after the Effective Date, *** dollars
($***) in full satisfaction of costs (including attorneys’ and application fees) incurred prior to the Effective Date to apply for, prosecute, enforce, and maintain each Licensed Patent in those countries where Company intends to commercialize
Licensed Product pursuant to section 4.1 of this Agreement. This payment shall be non-refundable and not creditable against the Company’s other patent prosecution payment obligations. The Company shall be responsible for its pro-rata share
of ongoing patent costs, determined by the number of other licensees at the time such fees and costs were incurred, for such patent or patent application. Pro-rata share shall be calculated for each country the Company requests a license.

  

	***	 Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.

  

					
		  	15	  	 UW/Osmetech Non-Exclusive Patent License Agreement

UW Reference 7063-18921A

Original Two of Two

Page 15 of 16

 Exhibit B 

Royalty Report Form 

Date 
 Company
Name & Address 
  

					
	License Number	  	  
	  	

  

			
	 Reporting Period:
	  	 Report Due Date:

This report must be submitted regardless of whether royalties are owed. Please do not leave any column blank. State all information
requested below. 
  

							
	 Product Description
	  	Royalty Rate	  	Quantity/
Net Sales	  	Royalty Due
		  		  		  	

  

											
	 Report Completed by:
	  	 	  		 	 Total Royalties Due:
	 	 	  	
						
	 Telephone Number:
	  	 	  		 		 		  	

 If you have questions please contact: 

Please make check payable to: University of Washington 

 

					
		  	16	  	 UW/Osmetech Non-Exclusive Patent License Agreement

UW Reference 7063-18921A

Original Two of Two

Page 16 of 16Amended & Restated License Agmt - Roche Molecular Systems

 EXHIBIT 10.11 

AMENDED AND RESTATED CHEMICALLY MODIFIED 

ENZYMES KIT PATENT LICENSE AGREEMENT 

This License Agreement (“Agreement”) is made by and between Roche Molecular Systems, Inc., a Delaware
corporation having an office at 4300 Hacienda Drive, Pleasanton, California 94588, USA and F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, CH-4070 Basel, Switzerland (hereinafter jointly referred to as “ROCHE”) and Osmetech Molecular
Diagnostics, 757 S. Raymond Avenue, Pasadena, CA 91105 (hereinafter referred to as “LCE”) hereafter collectively referred to as “The Parties”. 

PREAMBLE 
 A. ROCHE owns
or controls certain Licensed Patents relating to chemically modified thermostable DNA polymerases, also known as “Hot Start Enzymes,” for use in polymerase chain reaction (“PCR”) technology. 

B. LCE wants to incorporate Licensed Products into LCE’s Complete Diagnostic Kits for sale into the Licensed Field. 

C. LCE wants to convey to End Users with the sale of LCE’s Complete Diagnostic Kits the right to use the Complete Diagnostic Kits in
the Licensed Field. 
 D. ROCHE is willing to grant to LCE a non-exclusive, world-wide license under its Licensed Patents in
order to allow LCE to incorporate Licensed Products into LCE’s Complete Diagnostic Kits for the Licensed Field, and to convey with the sale of such Complete Diagnostic Kits the right to use the Complete Diagnostic Kits in the Licensed Field.

 E. ROCHE and LCE previously entered into two Roche Chemically Modified Enzymes Patent License Agreements effective as of
May 14 and June 1, 2007 (the “Prior Agreements”) which Prior Agreements are each hereby amended, restated and superseded in their entirety by this Agreement. 

 

	1.	 Definitions 

For the purpose of this Agreement, and solely for that purpose, the terms set forth herein shall be defined as follows: 

 

	1.1.	 “Affiliate” means with respect to a Party: (i) an organization, which directly or indirectly controls such Party; or
(ii) an organization, which is directly or indirectly controlled by such Party; or (iii) an organization, which is controlled, directly or indirectly, by the ultimate parent company of such Party. For purposes of this Section, control is
defined as owning fifty percent (50%) or more of the voting stock of a company or having otherwise the power to govern the financial and the operating policies or to appoint the management of an organization. The term “Affiliate” of
ROCHE shall not include Genentech, Inc., 1 DNA Way, South San Francisco, California 94080-4990, U.S.A. or Chugai Pharmaceutical Co., Ltd, 1-1, Nihonbasshi-Muromachi 2-chome, Chuo-ku Tokyo, 103- 8324, Japan, or the respective subsidiaries of said
companies. 

  

					
	 Osmetech – Contract No. 17852
	  	1	  	

 The term “Affiliate” includes organizations that meet any of the
above criteria at any time during the term of this Agreement and excludes organizations that cease to meet any of the above criteria at any time during the term of this Agreement. 

 

	1.2.	 “Complete Diagnostic Kit” means a LCE manufactured and trademarked kit covered by one or more Valid Claims of the Licensed Patents,
not covered by any ROCHE patents (including, but not limited to, U.S. Patent Nos. 5,210,015; 5,487,972; 5,804,375; 6,214,979; 5,994,056; 6,171,785 and their foreign counterparts) other than the Licensed Patents and dedicated for use for PCR in the
Licensed Field, and which LCE manufactured and trademarked kit is comprised of, at a minimum, the essential active reagents used in the practice of PCR for nucleic acid testing in the Licensed Field. For the avoidance of doubt and for the sake of
clarification, ASRs (Analyte Specific Reagents) are not Complete Diagnostic Kits. 

  

	1.3.	 “Effective Date” means the date on which the last signatory to this Agreement executes the Agreement. 

 

	1.4.	 “End User” means the customers, such as but not limited to doctors, hospitals, testing and research institutions, clinical or other
testing laboratories which perform diagnostic services or diagnostic testing using a Complete Diagnostic Kit. 

  

	1.5.	 “Licensed Field” means the field of use consisting of products or processes for the measurement, observation or determination of a
disease, disease state or genetic predisposition to a disease, by detecting, quantitating, distinguishing and/or monitoring nucleic acids in samples of material originating from a human being for the medical management for that human being, but
excluding (i) human identity testing, and (ii) the following human disease targets: Hepatitis A Virus, Hepatitis B Virus, Hepatitis C Virus, Human Immunodeficiency Virus, Human Papilloma Virus and Parvovirus B19; provided, however, that
the said exclusions for the Human Papilloma Virus and Parvovirus B19 disease targets shall be limited to three (3) years from the Effective Date after which time the Human Papilloma Virus and Parvovirus B19 disease targets shall be included
within the Licensed Field subject to the royalty and other terms and conditions of this Agreement. 

  

	1.6.	 “Licensed Patents” means only the United States patents listed in Schedule A to this Agreement, and any patent issuing from
any divisional, continuation, or continuation-in- part application (but specifically excluding any patent issuing from any continuation-in- part application that has claims directed to subject matter patentably distinct from that disclosed or
claimed in the parent patent or application) of a listed patent; and any reissue, re-examination, extension, and corresponding foreign patents of any of the foregoing. 

 

	1.7.	 “Licensed Product” means a chemically modified thermostable DNA polymerase, the manufacture, use or sale of which is covered by one
or more Valid Claims of the Licensed Patents, sold by ROCHE (directly or through its distributor) or made and sold by a supplier licensed to make and sell the same. 

 

					
	 Osmetech – Contract No. 17852
	  	2	  	

	1.8.	 “Net Sales” means the gross invoice price for sales or transfers by LCE or its Affiliates to End Users of all Complete Diagnostic
Kits less deductions for returns (including withdrawals and recalls), sales rebates (i.e. price reduction), volume (i.e. quantity) discounts, sales taxes and other taxes directly linked to the sales in the countries concerned. In addition to this
above computed adjusted gross invoice price, all other expenses which may occur like custom duties, transportation costs and other direct expenses shall be covered by a lump deduction
of            *** percent (***%) of the above computed adjusted gross invoice price. 

In the event LCE or its Affiliates are unable to account for the gross invoice price for sales or transfers of Complete
Diagnostic Kits to End Users, the Net Sales shall be calculated as the gross invoice price for sales or transfers by LCE or its Affiliates to distributors, agents or wholesalers multiplied by 1.35. 

In the event that (i) a Complete Diagnostic Kit is sold or transferred by LCE in such a way that the gross invoice
price for the sale or transfer of such Complete Diagnostic Kit is less than fair market value or does not fairly represent an actual independent arm’s- length transaction price for such Complete Diagnostic Kit, (ii) LCE transfers any
Complete Diagnostic Kit to an Affiliate which becomes an End User, or (iii) LCE uses any Complete Diagnostic Kit as an End User, then Net Sales shall be determined by reference to the gross invoice price for the Complete Diagnostic Kit sold or
transferred which would be applicable in an arm’s-length transaction with an unrelated third party by applying the average transaction price for Complete Diagnostic Kits in arms-length transactions for the previous twelve (12) month period
or, if no average transaction price of such Complete Diagnostic Kit is available for such period, at a reasonable value based upon the average transaction prices of other products available in the marketplace similar to such Complete Diagnostic Kit.

  

	1.9.	 “Territory” means world-wide. 

  

	1.10.	 “Valid Claim” means, in any country, the claim of an issued patent which (a) has not expired, (b) has not been
disclaimed, or (c) has not been revoked, held invalid or otherwise declared unenforceable by a tribunal of competent jurisdiction over such claim in such country from which no further appeal has or may be taken. Whether a patent claim is a
Valid Claim shall be determined on a country-by-country basis. 

  

	2.	 License 

  

	2.1.	 Subject to the terms and conditions of this Agreement, ROCHE hereby grants to LCE and its Affiliates a non-exclusive and non-transferable royalty
bearing license, without the right to sublicense, under the Licensed Patents in the Territory with the rights to: a) incorporate Licensed Products into LCE’s Complete Diagnostic Kits, b) make, offer to sell and sell such Complete Diagnostic
Kits in the Licensed Field, and c) convey with the sale of such Complete Diagnostic Kits the right to use the Complete Diagnostic Kits under the Licensed Patents in the Licensed Field. LCE and its Affiliate’s right to use

  

	***	 Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.

  

					
	 Osmetech – Contract No. 17852
	  	3	  	

	 	
Complete Diagnostic Kits includes the right to perform evaluations and validations of Complete Diagnostic Kits, but specifically does not include the right to use Complete Diagnostic Kits for the
performance of diagnostic services or testing, except that LCE and its Affiliates may use Complete Diagnostic Kits as End Users provided that royalties are paid thereon in accordance with Section 3.2. 

 

	2.2.	 The license granted by ROCHE herein to LCE and its Affiliates may be used solely for the purposes expressed above in Section 2.1. Except for
such grants, no further licenses or rights under the Licensed Patents or other patents owned or controlled by ROCHE are granted or given to LCE, its Affiliates or an End User in or under this Agreement, either expressly or by implication.

  

	3.	 Fees & Royalties 

  

	3.1.	 In consideration of the license granted in Article 2 of this Agreement, LCE has paid to ROCHE a non-creditable, non-refundable license issuance fee
of US dollars *** (USD ***), which fee was paid pursuant to the Prior Agreements, the receipt of which is hereby acknowledged. 

The payment required above was made to ROCHE pursuant to the Prior Agreements to the following account: 

UBS AG, Zürich, Switzerland 

SWIFT Code: *** 

IBAN No. *** 

Account No. *** 

For the account of F. Hoffmann-La Roche Ltd. with the reference: Contract No. 16536, license issuance fee

  

	3.2.	 As additional consideration for the rights and license granted herein, LCE shall pay to ROCHE royalties equal to
            *** percent (***%) of its Net Sales during the term of this Agreement commencing as of the Effective Date of this Agreement. 

No royalties shall be paid on sales of Complete Diagnostic Kits between LCE and its Affiliates, when the Affiliate is not
the End User of such Complete Diagnostic Kit, but acts as LCE’s distributor. In such event royalties shall be due and payable on the Net Sales of such Complete Diagnostic Kit by such Affiliates to third parties. 

 

	4.	 Reports, Payments, and Taxes 

  

	4.1.	 LCE shall, within sixty (60) days after December 31 and June 30 of each year, provide to the trustee mentioned in Schedule B
or another trustee as provided to LCE by ROCHE, a true and accurate royalty report. This report shall be in accordance with the royalty report form attached hereto as Attachment I. This report shall be on a U.S./ex-U.S. basis and shall give
such particulars of the business conducted by LCE during the preceding six (6) calendar months as are pertinent to an accounting for any royalty due under this Agreement, and shall include at least the following: 

 

	 	a)	 Separately itemized quantities of Complete Diagnostic Kits sold or otherwise transferred by LCE and its Affiliates during those six (6) months;

  

	***	 Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.

  

					
	 Osmetech – Contract No. 17852
	  	4	  	

	 	b)	 the cumulative gross invoice price of sales of each Complete Diagnostic Kit; 

 

	 	c)	 the Net Sales of each Complete Diagnostic Kit; and 

 

	 	d)	 the calculation of royalties due to ROCHE. If no royalties are due, it shall be so reported. 

The correctness and completeness of each such report shall be attested to in writing by a responsible financial officer
of LCE. 
 Simultaneously with the delivery of each such royalty report to the trustee, LCE shall pay to the
trustee the royalty due for the period covered by such a report. Royalties due to ROCHE shall be paid on or before the due date to the address stated in Schedule B or to any address that ROCHE may advise LCE in writing. Each royalty report of LCE
will be released by the trustee to ROCHE after one (1) calendar year following the royalty reporting period. 
  

	4.2.	 Royalties payable hereunder shall be made without any deductions, except for withholding tax or any other fiscal deductions from time to time
required by the government of any country. All such payments shall be made in US Dollars, or in such other currency as ROCHE may from time to time direct (so far as legally permissible). Any necessary currency conversion shall be at the rate for
buying funds as quoted by the Wall Street Journal for the last business day of the period to which such payments relate. 

  

	4.3.	 Withholding tax, if any, levied by a government of any country of the Territory on payments made by LCE to ROCHE hereunder shall be borne by ROCHE.
LCE will pay such withholding tax to the respective taxing authorities and will deduct such amount from the royalty due to ROCHE. LCE shall use its best efforts to enable ROCHE to claim exception therefrom under any double taxation or similar
agreement in force and shall produce to ROCHE proper evidence of payments of all withholding taxes. 

  

	4.4.	 LCE shall keep a complete and accurate set of books and records relating to the quantity of Complete Diagnostic Kits shipped by or for LCE and its
Affiliates and the sales of Complete Diagnostic Kits by LCE and its Affiliates. Such books and records shall contain sufficient detail to substantiate the computation of the Net Sales of Complete Diagnostic Kits and the amount of royalties payable
under this Article 4 as well as all other information in the statement of account provided for herein, and shall be maintained by LCE for a period of not less than three (3) years from the date of such sales. 

 

	4.5.	 ROCHE shall be entitled, upon reasonable notice to LCE, to have such books and records inspected by an independent certified public accounting firm
retained by ROCHE and reasonably acceptable to LCE (which acceptance shall not be unreasonably withheld), provided that any such inspection occurs during LCE’s normal business hours not more than once in any calendar year. ROCHE also shall be
entitled to have the books and records of each of LCE’s Affiliates relating to the quantity of Complete Diagnostic Kits 

 

					
	 Osmetech – Contract No. 17852
	  	5	  	

	 	
shipped by or for such Affiliate and such Affiliate’s sales of Complete Diagnostic Kits inspected, upon reasonable notice to such Affiliate, by an independent certified public accounting
firm retained by ROCHE and reasonably acceptable to such Affiliate, provided that any such inspection occurs during such Affiliate’s normal business hours not more than once in any calendar year. ROCHE agrees that all inspected information
shall be confidential to LCE and LCE’s Affiliates. 

  

	4.6.	 Any person conducting an inspection on behalf of ROCHE will be required to protect the confidentiality of such information and shall provide to
ROCHE a report only of the ultimate conclusions resulting from such inspection. Except as provided below, LCE shall pay promptly to ROCHE the amount of any royalties determined by such an inspection to be outstanding, along with interest accrued up
to and including the date of payment as provided in this Article 4. The costs of such an inspection shall be borne by ROCHE; provided, however, that, if such inspection determines that the royalties paid by LCE for any period were at least
            *** percent (***%) less than the royalties otherwise due and payable, then LCE shall reimburse ROCHE for the costs of such inspection. If such inspection determines that LCE has
overpaid the amount of royalties otherwise due and payable for the inspected period, then ROCHE shall credit the amount of such overpayment to LCE against future royalties payable by LCE. 

 

	4.7.	 If LCE fails to pay any amount specified under this Agreement after the due date thereof, the amount owed shall bear interest of
            *** percent (***%) per month from the due date until paid, provided, however, that if this interest rate is held to be unenforceable for any reason, the interest rate shall be
the maximum rate allowed by law at the time the payment is due. 

  

	5.	 Term and Termination 

  

	5.1.	 Upon the execution of this Agreement by The Parties, the license under this Agreement shall commence on the Effective Date and, unless terminated
sooner as provided herein below or by mutual agreement, shall remain in effect until the last Licensed Patent having a Valid Claim will have expired. 

  

	5.2.	 Failure by either Party to this Agreement to comply with any of its obligations and conditions contained herein shall entitle the other Party to
give the Party in default written notice requiring it to cure such default. If the default is not cured within sixty (60) days after receipt of such notice, the notifying Party shall be entitled, without prejudice to any of its other rights
conferred on it by this Agreement, to terminate the entire Agreement by giving notice to take effect immediately. 

  

	5.3.	 Either Party may terminate this Agreement upon thirty (30) days written notice if, at any time, the other Party shall file a petition in
bankruptcy or insolvency before the courts or apply for an arrangement or for the appointment of a receiver or trustee for all of its assets or any part thereof, or if the other Party proposes a written agreement of composition or extension of its
debts or if the other Party shall be served with an 

  

	***	 Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.

  

					
	 Osmetech – Contract No. 17852
	  	6	  	

	 	 
involuntary petition against it, filed in any insolvency proceeding, and such petition shall not be dismissed within sixty (60) days after its filing, or if the other Party shall propose or
be a Party to any dissolution or liquidation, or if the other Party shall make an assignment for the benefit of creditors. 

  

	5.4.	 LCE shall have the right to terminate this Agreement at any time for any reason upon ninety (90) days prior written notice.

  

	5.5.	 Termination of this Agreement for any reason shall be without prejudice to any other remedies to which either Party is or thereafter becomes
entitled hereunder and shall not affect any obligations or rights accrued before termination hereunder, provided however, that LCE shall be obligated to make all payments required by Section 3.1 regardless of the date of any such termination.

  

	5.6.	 Upon early termination of this Agreement, LCE shall notify ROCHE of the stock of Complete Diagnostic Kits LCE and its Affiliates have on hand at the
date of any such termination and LCE shall pay the royalty thereon, upon which LCE shall be entitled to sell the said stock in a period of three (3) months and in accordance with the requirements of Articles 4 and 6.

  

	5.7.	 The following provisions shall survive the expiration or termination of this Agreement: Article 3, Article 4, Section 5.5, and Articles 7, 8,
10, 11 and 12. 

  

	6.	 Labeling 

LCE agrees that it shall mark conspicuously all Complete Diagnostic Kits made by or for it, and shall cause each of its Affiliates to mark
or have marked conspicuously all Complete Diagnostic Kits with the following legend or such alternative legend as shall be mutually agreed to by The Parties. LCE shall include the following notices or labels on all Complete Diagnostic Kits:

 THE PURCHASE OF THIS PRODUCT GRANTS THE PURCHASER RIGHTS UNDER CERTAIN ROCHE PATENTS TO USE IT SOLELY FOR PROVIDING HUMAN IN
VITRO DIAGNOSTIC SERVICES. NO GENERAL PATENT OR OTHER LICENSE OF ANY KIND OTHER THAN THIS SPECIFIC RIGHT OF USE FROM PURCHASE IS GRANTED HEREBY. 
  

	7.	 Negation of Warranties and Indemnity 

Nothing in this Agreement shall be construed as: 
  

	 	a)	 a warranty or representation by ROCHE as to the validity or scope of any Licensed Patent; 

 

	 	b)	 a warranty or representation that the sale of Complete Diagnostic Kits by LCE or its Affiliates and/or the use of such Complete Diagnostic Kits
(including Licensed Products) by LCE’s or its Affiliate’s customers is or will be free from infringement of patents not licensed hereunder; 

  

					
	 Osmetech – Contract No. 17852
	  	7	  	

	 	c)	 an obligation to bring or prosecute actions or suits against third parties for infringement of Licensed Patents; or 

 

	 	d)	 conferring by implication or otherwise any license or rights under any patents, know-how or other industrial property rights of ROCHE other than
expressly granted hereunder. 

  

	8.	 Confidentiality-Publicity 

  

	8.1.	 Information disclosed in the royalty reports to ROCHE by LCE in connection with this Agreement shall be considered confidential and proprietary and
ROCHE shall not disclose the same to any third party, and shall hold them in confidence for a period of five (5) years and will not use them other than as permitted under this Agreement, provided, however, that any information which is orally
disclosed to ROCHE shall not be considered confidential and proprietary. 

  

	8.2.	 The above obligations of confidentiality shall not be applicable to the extent: 

 

	 	a)	 such information is general public knowledge or, after disclosure hereunder, becomes general or public knowledge through no fault of ROCHE;

  

	 	b)	 such information can be shown by ROCHE by its written records to have been in its possession prior to receipt thereof hereunder;

  

	 	c)	 such information is received by ROCHE from any third party for use or disclosure by ROCHE without any obligation to LCE, provided, however, that
information received by ROCHE from any third party funded by LCE (e.g. consultants, subcontractors, etc.) shall not be released from confidentiality under this exception; or 

 

	 	d)	 the disclosure of such information is required or desirable to comply with or fulfill governmental requirements, submissions to governmental bodies,
or the securing of regulatory approvals. 

  

	9.	 Most Favored Licensee 

If after the Effective Date of this Agreement, ROCHE grants to any unrelated third party, a license of substantially the same scope as
granted to LCE herein but under more favorable royalty rates than those given to LCE under this Agreement, ROCHE shall promptly notify LCE of said more favorable royalty rates, and LCE shall have the right and option to substitute such more
favorable royalty rates for the royalty rates contained herein. LCE’s right to elect said more favorable royalty rates shall extend only for so long as and shall be conditioned on LCE’s acceptance of all the same conditions, favorable or
unfavorable, under which such more favorable royalty rates shall be available to such other third party. Upon LCE’s acceptance of all such terms of said third-party agreement, the more favorable royalty rates shall be effective as to LCE on the
effective date of such other third party license agreement. Notwithstanding the foregoing, in the event that ROCHE shall receive substantial other nonmonetary consideration, for example, such as intellectual property rights, as a part of the
consideration for its granting of 
  

					
	 Osmetech – Contract No. 17852
	  	8	  	

 
such license to a third party, then such consideration shall be taken into account for determining whether or not the third party has been granted more favorable royalty rates. 

 

	10.	 Miscellaneous 

  

	10.1.	 This Agreement and the license herein granted are personal to LCE and shall not be assignable or transferable by LCE unless LCE assigns or transfers
its rights or delegates its duties and obligations (in whole and not in part) under this Agreement to any third person which acquires all, or substantially all, of its assets and/or business relating to molecular diagnostics, provided that such
assignee or transferee duly and effectively assumes all of the obligations of LCE by an instrument reasonably satisfactory to ROCHE, and provided further, that in the case of LCE’s assignee or transferee, such assignee or transferee shall be
approved in writing by ROCHE prior to such assignment or transfer, which approval shall not be unreasonably withheld or delayed. Any assignment or transfer in violation of the provisions of this section shall be void and shall constitute a material
breach of this Agreement. 

  

	10.2.	 Effective as of the Effective Date, this Agreement amends, restates and supersedes the Prior Agreements in their entirety, provided however, that
any royalties that may have accrued under the Prior Agreements prior to the Effective Date shall be paid by LCE to ROCHE as provided in the Prior Agreements. This Agreement contains the entire agreement of the parties concerning its subject matter
and supersedes all previous agreements or understandings, whether written or oral, with respect to such subject matter. 

  

	10.3.	 No amendments or alterations of this Agreement shall be binding upon either Party unless in writing and duly signed by The Parties.

  

	10.4.	 All titles and captions in this Agreement are for convenience only and shall not be interpreted as having any substantive meaning.

  

	10.5.	 If any provision of this Agreement is held to be illegal, invalid or unenforceable in a final, unappealable order or judgment or under any present
or future law (such provision to be hereinafter referred to as an “Invalid Provision”), then such Invalid Provision shall be severed from this Agreement and shall be rendered inoperative. The Parties shall promptly negotiate in good
faith a lawful, valid and enforceable provision that is as similar in terms to such Invalid Provision as may be possible while giving effect to the future benefits and burdens accruing to The Parties hereunder; and the remaining provisions of this
Agreement shall remain binding on The Parties hereto. In the event that The Parties cannot agree on a provision to replace an Invalid Provision, then The Parties shall submit such disagreement for resolution in accordance with the procedures set
forth in Article 12 below. It is expressly agreed by The Parties that amounts previously paid by one Party to the other Party under this Agreement shall not be recoverable to the paying Party as part of the replacement of an Invalid Provision unless
this Agreement is invalidated within one (1) year from the Effective Date. 

  

					
	 Osmetech – Contract No. 17852
	  	9	  	

	10.6.	 No failure or delay on the part of either Party in the exercise of any power or right hereunder shall operate as a waiver thereof. No single or
partial exercise of any right or power hereunder shall operate as a waiver of such right or of any other right or power. 

The waiver by any Party of a breach of any provision of this Agreement shall not operate or be construed as a waiver of
any other or subsequent breach hereunder. 
  

	10.7.	 Wherever any provision of this Agreement uses the term “including” (or “includes”), such term shall be deemed to mean
“including without limitation” and “including but not limited to” (or “includes without limitation” and “includes but is not limited to”) regardless of whether the words “without limitation” or
“but not limited to” actually follow the term “including” (or “includes”). 

  

	10.8.	 Except where the context otherwise requires, wherever used, the singular shall include the plural and the word “or” is used in the
inclusive sense. 

  

	11.	 Notices 

  

	11.1.	 Any notice required or permitted to be given under this Agreement shall be considered properly given, upon receipt, if sent by registered mail or
personal courier delivery to the respective address of each Party as follows: 

  

			
	If to LCE:	  	 Osmetech Molecular Diagnostics

757 S. Raymond Avenue
 Pasadena, California 91105

 USA
 Attention: General
Counsel

		
	If to ROCHE:	  	 F. Hoffman-La Roche Ltd

Grenzacherstrasse 124
 CH-4070 Basel

Switzerland
 Attention: Diagnostic Division
Licensing

		
	With a copy to:	  	 Roche Molecular Systems, Inc.

4300 Hacienda Drive
 Pleasanton, California 94588

 USA
 Attention: Legal
Department

		
	And a copy to:	  	 Roche Molecular Systems, Inc.

4300 Hacienda Drive
 Pleasanton, California 94588

 USA
 Attention: Licensing Department

  

					
	 Osmetech – Contract No. 17852
	  	10	  	

	12.	 Arbitration and Governing Law 

  

	12.1.	 This Agreement shall be governed by and enforced in accordance with the laws of Switzerland. 

 

	12.2.	 In the event of any controversy or claim arising out of or relating to any provision of this Agreement or the breach thereof, The Parties shall try
to settle those conflicts amicably between themselves. 

  

	12.3.	 Should The Parties fail to agree, any controversy, dispute or claim which may arise out of or in connection with this Agreement or the breach,
termination or validity thereof shall be settled by final and binding arbitration pursuant to the Rules of Conciliation and Arbitration of the International Chamber of Commerce (Paris) as hereinafter provided: 

 

	 	a)	 The arbitration tribunal shall consist of one (1) or three (3) arbitrators. If The Parties cannot agree on one arbitrator each Party shall
nominate in the request for arbitration and the answer thereto one arbitrator, and the two (2) arbitrators so named will then jointly appoint a third arbitrator as chairman of the arbitration tribunal. If one Party fails to nominate an
arbitrator or, if The Parties’ arbitrators cannot agree on the person to be named as chairman within sixty (60) days, the court of arbitration of the International Chamber of Commerce shall make the necessary appointments for arbitrator or
chairman; 

  

	 	b)	 The arbitration proceedings shall be held in the English language. The place of arbitration shall be Zürich (Switzerland).

 IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed by their duly
authorized officers as of the Effective Date. 
  

									
	 F. HOFFMAN-LA ROCHE LTD
	 		 		 	
					
	 By:
	 	 /s/ illegible
	 		 	 By:
	 	 /s/ illegible

	 Title:
	 	 Licensing Manager
	 		 	 Title:
	 	 Legal Counsel

	 Date:
	 	 02/26/08
	 		 	 Date:
	 	 02/27/08

			
	 ROCHE MOLECULAR SYSTEMS, INC.
	 		 	 OSMETECH MOLECULAR DIAGNOSTICS

					
	 By:
	 	 /s/ illegible
	 		 	 By:
	 	 /s/ Bruce A. Huebner

	 Title:
	 	 S.V.P. Business
	 		 	 Title:
	 	 President

	 Date:
	 	 2/20/08
	 		 	 Date:
	 	 2/18/08

  

	
	 Apprv’d As To Form

RMS LAW DEPT.

	
	 /s/ LG

 

					
	 Osmetech – Contract No. 17852
	  	11	  	

 SCHEDULE A 

U.S. Patent No. 5,677,152 — Issued October 14, 1997 (process and kit claims only) Nucleic Acid Amplification Using
a Reversibly Inactivated Thermostable Enzyme 
 U.S. Patent No. 5,773,258 — Issued June 30, 1998 (process and
kit claims only) Nucleic Acid Amplification Using a Reversibly Inactivated Thermostable Enzyme 
 U.S. Patent
No. 6,127,155—Issued: October 3, 2000 (reaction mixture claims only) Stabilized Thermostable Nucleic Acid Polymerase Compositions Containing Non-Ionic Polymeric Detergents 

 

					
	 Osmetech – Contract No. 17852
	  	12	  	

 SCHEDULE B 

At present Treureva AG, Zürich, Switzerland is the appointed trustee. All royalty reports due are to be sent either via mail
or fax to the following address: 
 Treureva AG 

Mühlebachstrasse 25 
 P.O. Box 131

 CH-8024 Zürich 
 Switzerland

 To the attention of: Mr. Reto Kuhl 

Tel: +41 44 267 1717 
 Fax: +41 44 267 1711

 E-mail: rkuhl@treureva.ch 
 All
royalty payments due to ROCHE shall be wire transferred to the bank account as shown below: 
 Credit Suisse 

Bahnhofstrasse 53 

8070 Zürich 

Switzerland 

Account No. *** 

SWIFT Code: *** 

IBAN No. *** 

For the account of: Treureva AG 

With the reference: Contract No. 17852, payment period 
  

	***	 Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.

  

					
	 Osmetech – Contract No. 17852
	  	13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00174-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00174-of-00352.parquet"}]]